Does anyone think that the board is not performing their duty to shareholders by not giving some guidance on that UQ paper? Remember when the Whitehead Institute published the results of their yeast screening for 120,000 or so drugs and found PBT2 a leading hit compound. Prana were right on it with an announcement to the market. Contrast that to now. What has changed? Do they want the price lower? http://pranabio.com/news/pranas-alzheimers-disease-treatment-strategy-validated-independent-study/#.XGUC3s9KhE4
